Clinical Trials

The purpose of this study is to determine if therapeutic plasma exchange (TPE) can reduce cell surface proteins circulating in plasma, including soluble receptors and extracellular vesicles (EVs).

Background:

Proteins expressed on the tumor surface are the focus of many targeted therapies, including antibody-based treatments, antibody-drug conjugates (ADCs), T cell receptor (TCR) fusion constructs, and chimeric antigen receptor T-cell (CAR-T) products. These target proteins can be shed from the tumor surface into the plasma as a soluble receptor or an EV, which may prevent targeted treatments from reaching the tumor. High levels of soluble MSLN (sMSLN) is associated with poor ...

The purpose of this study is to determine safety of plasma infusion in APOE 44 patients.
 

The purpose of this study is to investigate how efficiently the study medication imlifidase reduces the amount of donor specific antibodies (DSA) in comparison with plasma exchange (PE) therapy, in patients who have an active antibody mediated rejection (AMR) after recently been kidney transplanted. The purpose is also to investigate and compare safety for these two treatments. 20 patients will be treated with imlifidase and 10 with PE.

This phase II trial compares therapeutic plasma exchange followed by enfortumab vedotin and pembrolizumab to standard of care next-line therapy for the treatment of patients with bladder or upper urinary tract cancers that have spread from where they first started (primary site) to other places in the body (metastatic) and that have not responded to previous treatment (refractory). TPE is a process that slowly removes a patient's blood through an intravenous or central line. The blood is sent through a machine that separates the plasma (the liquid part of blood) from other blood components (red cells, white cells, platelets). The ...

The purpose of this study is to determine the kinetics of sPD-L1 removal and regeneration by plasma exchange in patients with melanoma.